Previous 10 | Next 10 |
Applied Molecular Transport press release ( NASDAQ: AMTI ): Q2 GAAP EPS of -$0.93. Cash, cash equivalents and investments. As of June 30, 2022, cash and cash equivalents were $95.8 million. For further details see: Applied Molecular Transport GAAP EPS of -$0.93 ...
Announced positive top-line data for AMT-101 FILLMORE Phase 2 trial in chronic pouchitis Orphan indication with no FDA-approved products Company granted end of Phase 2 meeting with FDA to discuss advancing into Phase 3 development Announced top-line data for ...
Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...
The clinical-stage biotech Applied Molecular Transport ( NASDAQ: AMTI ) dropped ~38% in the pre-market Wednesday after the company said its lead candidate AMT-101 failed to outperform in combination with AbbVie’s ( ABBV ) blockbuster drug Humira in a Phase 2 trial...
Applied Molecular Transport ( AMTI ) -40% erasing yesterday's gain on ulcerative colitis candidate data . Kornit Digital ( KRNT ) -24% after pre-announcing weak Q2 results, Citi slashes price target . Lottery.com ( LTRY ) -15% . SOS ( SOS ...
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week 8 – Post hoc analysis of patients with shorter duration of ulcerative coli...
Shares of Applied Molecular Transport ( NASDAQ: AMTI ) are up ~4% in after-hours trading after the company said it will release top-line results from a phase 2 trial of AMT-101 for ulcerative colitis before Wednesday's opening bell. The trial enrolled biologic-naiv...
SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TN...
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced its participation in fireside chats at the following investor conferences: Event: Jefferies Global Heal...
Applied Molecular Transport (NASDAQ:AMTI) stock has lost 5.2% to $4.05 in Wednesday morning trade, after the clinical-stage biopharmaceutical company said it would prioritize its resources on its lead clinical programs, reduce its workforce and change up its management team. AMTI to...
News, Short Squeeze, Breakout and More Instantly...
Applied Molecular Transport Inc. Company Name:
AMTI Stock Symbol:
NASDAQ Market:
Applied Molecular Transport Inc. Website:
Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo ...
Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceut...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...